---
schema_version: "secwatch.filing_event.v1"
accession: "0000031791-26-000016"
form_type: "8-K"
ticker: "RVTY"
cik: "0000031791"
company_name: "REVVITY, INC."
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:36:37.675711+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Revvity Q1 adj EPS $1.06 beats $1.01 YoY; revenue $711M +7%; plans China IDX divestiture

## Summary
- Q1 GAAP EPS $0.37 vs $0.35 YoY; adjusted EPS $1.06 vs $1.01; revenue $711M (+7% YoY).
- Pro forma (ex-China IDX) revenue $687M, adj EPS $1.04 vs $0.95 YoY.
- Signed LOI to sell China Immunodiagnostics business for up to $200M; expects close by 2027.
- China IDX represented ~6% of FY2025 total revenue; definitive agreement expected Q2 2026.
- Full-year 2026 guidance updated on pro forma basis; management to discuss on call.

## SEC filing metadata
- accession: 0000031791-26-000016
- form_type: 8-K
- ticker: RVTY
- cik: 0000031791
- company_name: REVVITY, INC.
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/31791/000003179126000016/0000031791-26-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/31791/000003179126000016/pki-20260505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000031791-26-000016
- JSON: https://secwatch.observer/filing/0000031791-26-000016.json
- Plain text: https://secwatch.observer/filing/0000031791-26-000016.txt

## Key facts
- Earnings Releases
  REVVITY, INC. reported first quarter ended April 5, 2026 results: revenue $711 million, EPS $0.37.
  - Period: first quarter ended April 5, 2026
  - Revenue: $711 million
  - EPS: $0.37
  - Result: reported results
  source text: OR IMMEDIATE RELEASE May 5, 2026 Revvity Announces Financial Results for the First Quarter of 2026 • Revenue of $711 million; pro forma revenue of $687 million; 7% revenue growth; 3% organic gro wth; 6% pro forma organic growth • GAAP EPS from continuing operations of $0.37 ; adjusted EPS from continuing operations of $1.06 ; GAAP pro forma EPS from continuing operations of $0.40; pro forma adjusted EPS from continuing operations of $1.04 • Announces intention to divest China Immunodiagnostics business • Updates full year 2026 guidance WALTHAM, Mass.
  evidence_url: https://www.sec.gov/Archives/edgar/data/31791/000003179126000016/0000031791-26-000016-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.